ACCESS PHARMACEUTICALS ANNOUNCES EXCLUSIVE GLOBAL PLASMA THERAPEUTICS LICENSE, NEW MANAGEMENT AND NEW CORPORATE NAME

Print E-mail
Monday, 22 September 2014 09:47

Name Changed to PlasmaTech Biopharmaceuticals, Inc.

 

Proprietary, Disruptive Technology for the viagra sale Bioidentical Therapeutics Business

 

Dallas, TX and New York, NY, September 22, 2014 - ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, global license agreement with Plasma Technologies LLC ("PlasmaTech") for the development and buy viagra online commercialization of buying viagra in the us its proprietary plasma fractionation process.

Read more...
 

RELMADA THERAPEUTICS, INC. APPOINTS CHRISTOPHER W. JAMES AS SENIOR DIRECTOR OF viagra side effects CLINICAL DEVELOPMENT

Print E-mail
Thursday, 18 September 2014 19:04
New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of propecia 1mg chronic pain, announced today that it has appointed Mr. Christopher W. James to the viagra en gel position of cialis daily  Senior Director of Clinical Development.
Read more...
 

How to Pick Winning Biotechs Before the buy generic viagra online Herd

Print E-mail
Wednesday, 03 September 2014 19:34

Liana Moussatos of buy viagra canada Wedbush Securities doesn't wait for the catalyst to strike.

Read more...
 

Actinium Pharmaceuticals, Inc. Announces Launch of viagra uit india Additional Antibody Actinium-225 Labeling Program

Print E-mail
Wednesday, 16 July 2014 11:51
NEW YORK--Actinium Pharmaceuticals, Inc . (nyse mkt:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225.
Read more...
 

PV-10 Immune Mechanism Data to Be Presented at the best viagra American Association for Cancer Research Annual Meeting

Print E-mail
Thursday, 06 March 2014 12:01
KNOXVILLE, Tenn.-- Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT), a development-stage oncology and order cheap viagra dermatology biopharmaceutical company, announced that data will be presented by researchers from Moffitt Cancer Center in a poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Read more...
 


BioMedReports Neuralstem Announces ALS Long-Term Follow-Up Phase I Data; Tekmira Establishes Regulatory Framework For Emerge... http://t.co/EysnwsKezu
11hreplyretweetfavorite
BioMedReports Old drug may be key to new antibiotics http://t.co/Qan398733g
15hreplyretweetfavorite
BioMedReports Healthcare Review: Genetic Technologies, Progenics Pharmaceuticals, Repros Therapeutics, Tekmira Pharmaceutica... http://t.co/CDfXq9lB6R
17hreplyretweetfavorite
navigation
Benzinga.com supporter Seeking Alpha Certified